MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) is a publicly traded Healthcare sector company. As of May 21, 2026, MLTX trades at $17.04 with a market cap of $1.21B and a P/E ratio of -4.82. MLTX moved +4.09% today. Year to date, MLTX is +52.37%; over the trailing twelve months it is -57.67%. Its 52-week range spans $5.95 to $62.75. Analyst consensus is buy with an average price target of $29.15. Rallies surfaces MLTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes MLTX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $17.04 |
| Market Cap | $1.21B |
| P/E Ratio | -4.82 |
| EPS | $-3.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.75 |
| 52-Week Low | $5.95 |
| Volume | 344 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-230.32M |
| Gross Margin | 0.00% |
14 analysts cover MLTX: 0 strong buy, 10 buy, 2 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.15.